Maturity-onset diabetes of the young (MODY) is a highly heterogeneous group of monogenic and nonautoimmune diseases. Misdiagnosis of MODY is a widespread problem and about 5% of patients with type 2 diabetes mellitus and nearly 10% with type 1 diabetes mellitus may actually have MODY. Using next-generation DNA sequencing (NGS) to facilitate accurate diagnosis of MODY, this study investigated mutations in 13 MODY genes (HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, ABCC8, and KCNJ11). In addition, we comprehensively investigated the clinical phenotypic effects of the genetic variations identified. Fifty-one adult patients with suspected MODY and 64 healthy controls participated in the study. We identified 7 novel and 10 known missense mutations localized in PDX1, HNF1B, KLF11, CEL, BLK, and ABCC8 genes in 29.4% of the patient sample. Importantly, we report several mutations that were classified as “deleterious” as well as those predicted as “benign.” Notably, the ABCC8 p.R1103Q, ABCC8 p.V421I, CEL I336T, CEL p.N493H, BLK p.L503P, HNF1B p.S362P, and PDX1 p.E69A mutations were identified for the first time as causative variants for MODY. More aggressive clinical features were observed in three patients with double- and triple-heterozygosity of PDX1-KLF11 (p.E69A/p.S182R), CEL-ABCC8-KCNJ11 (p.I336, p.G157R/p.R1103Q/p.A157A), and HNF1B-KLF11 (p.S362P/p.P261L). Interestingly, the clinical effects of the BLK mutations appear to be exacerbated in the presence of obesity. In conclusion, NGS analyses of the adult patients with suspected MODY appear to be informative in a clinical context. These findings warrant further clinical diagnostic research and development in different world populations suffering from diabetes with genetic underpinnings.
Get full access to this article
View all access options for this article.
References
1.
AbreuGM, SoaresCAPD, TarantinoRM, et al. (2020). Identification of the first PAX4-MODY family reported in Brazil. Diabetes Metab Syndr Obes, 13, 2623–2631.
2.
AcarS, AbaciA, DemirK, et al. (2018). A novel de novo missense mutation in HNF4A resulting in sulfonylurea-responsive maturity-onset diabetes of the young. J Pediatr Res, 5, 156–160.
3.
AgladiogluSY, AycanZ, CetinkayaS, et al. (2016). Maturity onset diabetes of youth (MODY) in Turkish children: Sequence analysis of 11 causative genes by next generation sequencing. J Pediatr Endocrinol Metab, 29, 487–496.
4.
AnikA, CatliG, AbaciA, et al. (2015). Molecular diagnosis of maturity-onset diabetes of the young (MODY) in Turkish children by using targeted next-generation sequencing. J Pediatr Endocrinol Metab, 28, 1265–1271.
5.
Arslan AtesE, UstayO, PolatH, et al. (2021). Genetic and clinical characterization of patients with maturity-onset of diabetes of the young (MODY): Identification of novel variations. Balkan Med J, 38, 272–277.
6.
AykutA, KaracaE, OnayH, et al. (2018). Analysis of the GCK gene in 79 MODY type 2 patients: A multicenter Turkish study, mutation profile and description of twenty novel mutations. Gene, 641, 186–189.
7.
BennettJT, VastaV, ZhangM, et al. (2015). Molecular genetic testing of patients with monogenic diabetes and hyperinsulinism. Mol Genet Metab, 114, 451–458.
8.
BonnefondA, YengoL, PhilippeJ, et al. (2013). Reassessment of the putative role of BLK-p.A71T loss-of-function mutation in MODY and type 2 diabetes. Diabetologia, 56, 492–496.
9.
BorowiecM, LiewCW, ThompsonR, et al. (2009). Mutations at the BLK locus linked to maturity-onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci U S A, 106, 14460–14465.
10.
BowmanP, FlanaganSE, EdghillEL, et al. (2012). Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia, 55, 123–127.
11.
ChandraS, SrinivasanS, and BatraJ. (2021). Hepatocyte nuclear factor 1 beta: A perspective in cancer. Cancer Med, 10, 1791–1804.
12.
ChistiakovDA, PotapovVA, KhodirevDS, et al. (2008). The KCNJ11 E23K and ABCC8 exon 31 variants contribute to susceptibility to type 2 diabetes, glucose intolerance and altered insulin secretion in a Russian population. Diabetes Metab Syndr Clin Res Rev, 2, 185–191.
13.
ColcloughK, Bellanne-ChantelotC, Saint-MartinC, et al. (2013). Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. Hum Mutat, 34, 669–685.
14.
CovantevS, ChiriacA, PerciuleacL, and ZozinaV. (2016). Maturity onset diabetes of the young: Diagnosis and treatment options. Russ Open Med J, 5, e0402.
15.
Delgado-VegaAM, DozmorovMG, QuirósMB, et al. (2012). Fine mapping and conditional analysis identify a new mutation in the autoimmunity susceptibility gene BLK that leads to reduced half-life of the BLK protein. Ann Rheum Dis, 71, 1219–1226.
16.
DelvecchioM, PastoreC, and GiordanoP. (2020). Treatment options for MODY patients: A systematic review of literature. Diabetes Ther, 11, 1667–1685.
17.
DemirciDK, DarendelilerF, PoyrazogluS, et al. (2021). Monogenic childhood diabetes: Dissecting clinical heterogeneity by next-generation sequencing in maturity-onset diabetes of the young. OMICS, 25, 431–449.
18.
DengM, XiaoX, ZhouL, and WangT. (2019). First case report of maturity-onset diabetes of the young type 4 pedigree in a Chinese family. Front Endocrinol (Lausanne), 10, 406.
19.
DoriaA. (2005). Chapter 22: Genetics of type 2 diabetes. In: Joslin's Diabetes Mellitus, 14th Edition. Kahn CR, Weir GC, King GL, et al., eds. Lippincott Williams and Wilkins, Boston, MA, USA; 371–397.
20.
EdghillEL, OramRA, Owens, et al. (2008). Hepatocyte nuclear factor-1beta gene deletions—a common cause of renal disease. Nephrol Dial Transplant, 23, 627–635.
21.
EllardS, Bellanné-ChantelotC, HattersleyAT, European Molecular Genetics Quality Network (EMQN) MODYGroup. (2008). Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia, 51, 546–553.
22.
EllardS, and ColcloughK. (2006). Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1alpha (HNF1A) and 4alpha (HNF4A) in maturity-onset diabetes in the young. Hum Mutat, 27, 854–869.
23.
EstalellaI, RicaI, Perez de NanclaresG, et al. (2007). Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain. Clin Endocrinol, (Oxf).67, 538–546.
24.
FajansSS, BellGI, and PolonskyKS. (2001). Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med, 345, 971–980.
25.
FlanaganSE, ClauinS, Bellanné-ChantelotC, et al. (2009). Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat, 30, 170–180.
26.
GaoJ, AksoyBA, DogrusozU, et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6, pl1.
27.
GardnerDSL, and TaiES. (2012). Clinical features and treatment of maturity onset diabetes of the young (MODY). Diabetes Metab Syndr Obes, 5, 101–108.
28.
GoksenD, OzenS, KorkmazO, et al. (2013). The frequency of glucokinase, HNF1A and HNF4A gene mutations and their clinical aspects in suspected cases. Pediatr Diabetes, 14, 132–133.
29.
GragnoliC, StanojevicV, GoriniA, et al. (2005). IPF-1/MODY4 gene missense mutation in an Italian family with type 2 and gestational diabetes. Metabolism, 54, 983–988.
30.
HalilogluB, HysenajG, AtayZ, et al. (2016). GCK gene mutations are a common cause of childhood-onset MODY (maturity-onset diabetes of the young) in Turkey. Clin Endocrinol (Oxf), 85, 393–399.
31.
HansenL, UriosteS, PetersenHV, et al. (2000). Missense mutations in the human insulin promoter factor-1 gene and their relation to maturity-onset diabetes of the young and late-onset type 2 diabetes mellitus in Caucasians. J Clin Endocrinol Metab, 85, 1323–1326.
32.
HorikawaY, IwasakiN, HaraM, et al. (1997). Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet, 17, 384–385.
33.
JohansenCT, DubéJB, LoyzerMN, et al. (2014). LipidSeq: A next-generation clinical resequencing panel for monogenic dyslipidemias. J Lipid Res, 55, 765–772.
34.
JohanssonBB, TorsvikJ, BjørkhaugL, et al. (2011). Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): A protein misfolding disease. J Biol Chem, 286, 34593–34605.
35.
JuszczakA, and OwenK. (2014). Identifying subtypes of monogenic diabetes. Diabetes Manage, 4, 49–61.
36.
KaracaE, OnayH, CetinkalpS, et al. (2017). The spectrum of HNF1A gene mutations in patients with MODY 3 phenotype and identification of three novel germline mutations in Turkish population. Diabetes Metab Syndr 11 Suppl, 1, S491–S496.
37.
KaraoglanM, and NacarkahyaG. (2021). Clinical and laboratory clues of maturity-onset diabetes of the young and determination of association with molecular diagnosis. J Diabetes, 13, 154–163.
38.
KargesB, BergmannC, SchollK, et al. (2007). Digenic inheritance of hepatocyte nuclear factor-1alpha and -1beta with maturity-onset diabetes of the young, polycystic thyroid, and urogenital malformations. Diabetes Care, 30, 1613–1614.
39.
KimSH. (2015). Maturity-onset diabetes of the young: What do clinicians need to know?. Diabetes Metab J, 39, 468–477.
40.
KomazecJ, ZdravkovicV, SajicS, et al. (2019). The importance of combined NGS and MLPA genetic tests for differential diagnosis of maturity onset diabetes of the young. Endokrynol Pol, 70, 28–36.
41.
KyitharMP, BaconS, PannuKK, et al. (2011). Identification of HNF1A-MODY and HNF4A-MODY in Irish families: Phenotypic characteristics and therapeutic implications. Diabetes Metab, 37, 512–519.
42.
MohanV, RadhaV, NguyenTT, et al. (2018). Comprehensive genomic analysis identifies pathogenic variants in maturity-onset diabetes of the young (MODY) patients in South India. BMC Med Genet, 19, 22.
43.
MolvenA, RingdalM, NordbøAM, et al. (2008). Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes, 57, 1131–1135.
44.
NeveB, Fernandez-ZapicoME, Ashkenazi-KatalanV, et al. (2005). Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci U S A, 102, 4807–4812.
45.
NkongeKM, NkongeDK, and NkongeTN. (2020). The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY). Clin Diabetes Endocrinol, 6, 20.
46.
OliveiraSC, NevesJS, PerezA, and CarvalhoD. (2020). Maturity-onset diabetes of the young: From a molecular basis perspective toward the clinical phenotype and proper management. Endocrinol Diabetes Nutr, 67, 137–147.
47.
OsbakKK, ColcloughK, Saint-MartinC, et al. (2009). Update on mutations in glucokinase (GCK), which cause maturity onset diabetes of the young, permanent neonatal diabetes, and hyper-insulinemic hypoglycemia. Hum Mutat, 30, 1512–1526.
48.
OvsyannikovaAK, RymarOD, ShakhtshneiderEV, et al. (2016). ABCC8-related maturity-onset diabetes of the young (MODY12): Clinical features and treatment perspective. Diabetes Ther, 7, 591–600.
49.
OzdemirTR, KirbiyikO, DundarBN, et al. (2018). Targeted next generation sequencing in patients with maturity-onset diabetes of the young (MODY). J Pediatr Endocrinol Metab, 31, 1295–1304.
50.
OzsuE, CizmeciogluFM, Yesiltepe MutluG, et al. (2018). Maturity onset diabetes of the young due to glucokinase, HNF1-A, HNF1-B, and HNF4-A mutations in a cohort of Turkish children diagnosed as type 1 diabetes mellitus. Horm Res Paediatr, 90, 257–265.
51.
PappaKI, GazouliM, EconomouK, et al. (2011). Gestational diabetes mellitus shares polymorphisms of genes associated with insulin resistance and type 2 diabetes in the Greek population. Gynecol Endocrinol, 27, 267–272.
52.
PearsonER, LiddellWG, ShepherdM, et al. (2000). Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: Evidence for pharmacogenetics in diabetes. Diabet Med, 17, 543–545.
53.
PicciniB, ArtusoR, LenziL, et al. (2016). Clinical and molecular characterization of a novel INS mutation identified in patients with MODY phenotype. Eur J Med Genet, 59, 590–595.
54.
PlengvidhyaN, KooptiwutS, SongtaweeN, et al. (2007). PAX4 mutations in Thais with maturity onset diabetes of the young. J Clin Endocrinol Metab, 92, 2821–2826.
55.
PrudenteS, JungtrakoonP, MarucciA, et al. (2015). Loss-of-function mutations in APPL1 in familial diabetes mellitus. Am J Hum Genet, 97, 177–185.
56.
PuglieseA. (2005). The insulin gene in type 1 diabetes. IUBMB Life, 57, 463–468.
57.
RaederH, JohanssonS, HolmPI, et al. (2006). Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet, 38, 54–62.
58.
RaederH, McAllisterFE, TjoraE, et al. (2014). Carboxyl-ester lipase maturity-onset diabetes of the young is associated with development of pancreatic cysts and upregulated MAPK signaling in secretin-stimulated duodenal fluid. Diabetes, 63, 259–269.
59.
RamosM, GeistlingerL, OhS, et al. (2020). Multiomic integration of public oncology databases in bioconductor. JCO Clin Cancer Inform, 4, 958–971.
60.
SarmadiA, MohammadiA, TabatabaeiF, et al. (2020). Molecular genetic study in a cohort of Iranian families suspected to maturity-onset diabetes of the young, reveals a recurrent mutation and a high-risk variant in the CEL gene. Adv Biomed Res, 9, 25.
61.
SchoberE, RamiB, GrabertM, et al. (2009). Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: Experience from a large multicentre database. Diabet Med, 26, 466–473.
62.
StoffelM, and DuncanSA. (1997). The maturity-onset diabetes of the young (MODY1) transcription factor HNF4α regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A, 94, 13209–13214.
63.
TaoT, YangY, and HuZ. (2020). A novel HNF1B mutation p.R177Q in autosomal dominant tubulointerstitial kidney disease and maturity-onset diabetes of the young type 5: A pedigree-based case report. Medicine (Baltimore), 99, e21438.
64.
ThomasCP, ErlandsonJC, EdghillEL, et al. (2008). A genetic syndrome of chronic renal failure with multiple renal cysts and early onset diabetes. Kidney Int, 74, 1094–1099.
65.
TorsvikJ, JohanssonS, JohansenA, et al. (2010). Mutations in the VNTR of the carboxyl-ester lipase gene (CEL) are a rare cause of monogenic diabetes. Hum Genet, 127, 55–64.
66.
UcakturkSA, GunindiF, CeylanerS, et al. (2017). A novel genetic mutation in a Turkish family with GCK-MODY. Int J Diabetes Dev Ctries, 37, 323–326.
67.
UrakamiT. (2019). Maturity-onset diabetes of the young (MODY): Current perspectives on diagnosis and treatment. Diabetes Metab Syndr Obes, 12, 1047–1056.
68.
UrbanovaJ, RypáčkováB, ProcházkováZ, et al. (2014). Positivity for islet cell autoantibodies in patients with monogenic diabetes is associated with later diabetes onset and higher HbA1c level. Diabet Med, 31, 466–471.
69.
UshijimaK, NarumiS, OgataT, et al. (2019). KLF11 variant in a family clinically diagnosed with early childhood-onset type 1B diabetes. Pediatr Diabetes, 20, 712–719.
70.
Van der AuweraGA, CarneiroMO, HartlC, et al. (2013). From FastQ data to high confidence variant calls: The Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics, 43, 11.10.1–11.10.33.
71.
WangX, SterrM, Ansarullah, et al. (2019). Point mutations in the PDX1 transactivation domain impair human β-cell development and function. Mol Metab, 24, 80–97.
72.
WeberS, MoriniereV, KnüppelT, et al. (2006). Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: Results of the ESCAPE study. J Am Soc Nephrol, 17, 2864–2670.
73.
WinterWE. (2003). Newly defined genetic diabetes syndromes: Maturity onset diabetes of the young. Rev Endocr Metab Disord, 4, 43–51.
YalcintepeS, Ozguc ComlekF, GurkanH, et al. (2021). The application of next generation sequencing maturity onset diabetes of the young gene panel in Turkish patients from Trakya region. J Clin Res Pediatr Endocrinol, 13, 320–331.
76.
YamagataK, FurutaH, OdaN, et al. (1996). Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature, 384, 458–460.
77.
ZhangJ, JiangY, LiL, et al. (2020). The first E59Q mutation identified in the NEUROD1 gene in a Chinese family with maturity-onset diabetes of the young: an observational study. J BioX Res, 3, 109–115.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
